Similar content being viewed by others Introduction Central to metabolic reprogramming is the dysregulation of Glutamine (Gln) metabolism, which has emerged as a critical aspect of cancer pathophysiology
Swaby RF, Jordan VC: Low-dose estrogen therapy to reverse acquired antihormonal resistance in the treatment of breast cancer
Endocrine, 49(2), 307323
doi: 10.1016/j.jocn.2009.01.031
Patient heterogeneity, long disease course, and variability in clinical presentation complicate recruitment, stratification, and outcome measurement
Relevant conventional findings include creatinine, eGFR, BUN, CMP CO, electrolytes, hydration, blood pressure, glucose, medication use and known kidney disease